Affinity matrix bearing tumor-associated carbohydrate-or glycopeptide-based antigens and uses thereof
OwnerSamuel J. Danishefsky, Kenneth O. Lloyd +2inventors
InventorsSamuel J. Danishefsky, Kenneth O. Lloyd, Zhi-Guang Wang, Lawrence J. Williams
Life of this patent
Estimating the term…
Abstract
An affinity matrix having a tumor-associated carbohydrate- or glycopeptide-based antigen bound to the matrix is provided. The affinity matrix is used to isolate, characterize, and quantitate functional antibodies or antigen-binding molecules to the tumor-associated carbohydrate- or glycopeptide-based antigen. The invention also provides a method of preparing the affinity matrix. In addition the invention provides for diagnostic and therapeutic uses of the isolated antibodies or antigen-binding molecules.
Claims62
An affinity matrix comprising tumor-associated carbohydrate- or glycopeptide-based antigen bound to the matrix.
An affinity matrix comprising synthetic tumor-associated carbohydrate- or glycopeptide-based antigen bound to the matrix.
An affinity matrix comprising monomeric or clustered globo-H-oligosaccharide bound to an agarose support.
An affinity matrix comprising monomeric or clustered Lewis Y oligosaccharide bound to an agarose support.
An affinity matrix comprising monomeric or clustered Tn bound to an agarose support.
An affinity matrix comprising monomeric or clustered TF bound to an agarose support.
A method for preparing an affinity matrix comprising the steps of:
- a) providing monomeric or clustered tumor-associated carbohydrate- or glycopeptide-based antigen, or a combination thereof;
- and
- b) contacting said carbohydrate- or glycopeptide-based antigen with a solid support, whereby the step of contacting effects binding of the antigen to the support.
A method for isolating antibodies or antigen-binding molecules comprising the steps of:
- providing a solution comprising antibodies or antigen-binding molecules;
- contacting the solution with an affinity matrix, which affinity matrix comprises carbohydrate- or glycopepetide-based antigens that are capable of binding to said antibodies or antigen-binding molecules;
- and
- eluting the antibodies or antigen-binding molecules from the affinity matrix.
A method of detecting a cancer in a subject comprising the steps of:
- (a) providing a solution comprising blood fluids from a subject;
- (b) contacting the solution with an affinity matrix, wherein said affinity matrix comprises tumor-associated carbohydrate- or glycopeptide-based antigens bound to the matrix;
- (c) treating the affinity matrix with a reagent suitable to elute antibodies or antigen-binding molecules bound to the tumor-associated carbohydrate- or glycopeptide-based antigens present in the affinity matrix;
- and
- (d) determining the presence of antibodies or antigen-binding molecules.
A method of treating cancer in a subject comprising the steps of:
- (a) isolating antibodies or antigen-binding molecules, wherein the step of isolating comprises:
- providing a solution comprising blood fluids from a subject;
- contacting the solution with an affinity matrix, whereby said affinity matrix comprises tumor-associated carbohydrate- or glycopeptide-based antigens;
- and
- treating the affinity matrix with a reagent suitable to elute antibodies or antigen-binding molecules bound to the tumor-associated carbohydrate- or glycopeptide-based antigens present in the affinity matrix;
- (b) conjugating one or more therapeutic agents to the isolated antibodies or antigen-binding molecules;
- and
- (c) re-administering the conjugated antibodies or antigen-binding molecules to the subject.
A method of imaging cancer metastases in a subject comprising the steps of:
- (a) isolating antibodies or antigen-binding molecules, wherein the step of isolating comprises:
- providing a solution comprising blood fluids from a subject;
- contacting the solution with an affinity matrix, whereby said affinity matrix comprises tumor-associated carbohydrate- or glycopeptide-based antigen;
- and
- treating the affinity matrix with a reagent suitable to elute antibodies or antigen-binding molecules bound to the tumor-associated carbohydrate- or glycopeptide-based antigens present in the affinity matrix;
- (b) labeling the isolated antibodies or antigen-binding molecules with imaging agents;
- and
- (c) re-administering the labeled antibodies or antigen-binding molecules to the subject.
Dependencies are inferred from the claim text.